Explore Stanford technologies available for licensing:

High-grade gliomas, such as glioblastoma and diffuse midline glioma, are currently incurable diseases with an urgent need for novel therapeutic approaches.

Researchers at Stanford have developed constitutively active, programmable synthetic cytokine receptors capable of polarizing human macrophages to a variety of user-defined cell states which may be useful for therapeutic applications.

Stanford researchers have developed REULR (Receptor Elimination by E3 Ubiquitin Ligase Recruitment), a mix and match nanobody (VHH)-based extracellular targeted protein degradation (eTPD) platform.

Hematological cancers like non-Hodgkin's lymphoma have seen a revolution in care due to the advances of targeted cell therapies like CAR-T. However, not all blood cancers have enjoyed the same benefit, hampered by the lack of actionable and specific blood cell targets.

Stanford researchers have identified that increased oxidative stress is a key molecular signature of fatigue-based conditions including Long COVID and myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS).

Researchers at Stanford have developed a general software framework that reconstructs high-resolution spatial fields from sparse, irregular, or noisy measurements.

Stanford researchers at the Chichilnisky lab have patented an artificial retina framework for dynamic electrical stimulation to improve the performance of electronic visual implants.

Stanford scientists have discovered a novel method for treating neuroendocrine tumors by engineering T cells with Synthetic Notch (SynNotch) circuits that enable precise and durable tumor targeting while overcoming antigen heterogeneity.

Stanford researchers have developed a macrophage-targeted PEGylated liposome ("PEGosome") platform that selectively delivers polyethylene glycol (PEG) to inflammatory monocytes and macrophages driving neuroinflammation in diseases such as multiple sclerosis (MS), Alzheimer's d

Stanford scientists have developed an innovative technique for fixating implants to bone.

Stanford researchers have found that inhibiting 15-prostaglandin dehydrogenase (15-PGDH), which breaks down prostaglandin E2 (PGE2), can improve cardiac function in diseased and aged hearts.

Stanford researchers have developed a first-to-market personalized surgical system that optimizes quadriceps tendon (QT) harvesting for ACL reconstruction.

Researchers at Stanford have developed ComBind, a computational platform that improves prediction of how drug molecules bind to their protein targets by combining structural modeling with readily available binding data from other molecules.

Stanford scientists have established a modeling based proof-of-concept for a subsurface logging method that reliably distinguishes hydrogen from methane using thermal conductivity, overcoming a major limitation of existing oil-and-gas logging technologies.

Stanford scientists have developed an optical imaging system that enables simultaneous monitoring of multiple neural signals across large brain regions with high temporal and spatial resolution.